Yifan Xinfu Pharmaceutical Co Ltd (002019) — Working Capital to Net Assets Ratio

Latest as of March 2026: 11.1%

Yifan Xinfu Pharmaceutical Co Ltd (002019) has a Working Capital to Net Assets ratio of 11.1% as of March 2026. Working capital of CN¥975.20 Million (current assets of CN¥3.87 Billion minus current liabilities of CN¥2.89 Billion) is measured against net assets of CN¥8.76 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 002019 net asset quality score to measure how much of total assets are equity-financed.

WC/NA Ratio

11.1%
Working Capital / Net Assets

Working Capital

CN¥975.20 Million
CNY

Current Assets

CN¥3.87 Billion
CNY

Current Liabilities

CN¥2.89 Billion
CNY

Yifan Xinfu Pharmaceutical Co Ltd Working Capital to Net Assets (2001–2025)

This chart shows how Yifan Xinfu Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 25 annual periods from 2001 to 2025. As of March 2026, the ratio stands at 11.1%, reflecting working capital of CN¥975.20 Million against net assets of CN¥8.76 Billion CNY. Check 002019 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Annual Working Capital to Net Assets for Yifan Xinfu Pharmaceutical Co Ltd (2001–2025)

The table below presents the year-by-year Working Capital to Net Assets ratio for Yifan Xinfu Pharmaceutical Co Ltd from 2001 to 2025, covering 25 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 002019 stock market capitalisation.

Year WC/NA Ratio Working Capital (CNY) Net Assets Current Assets Current Liabilities Change (pp)
2025 10.2% CN¥888.84 Million CN¥8.71 Billion CN¥3.92 Billion CN¥3.03 Billion ▲ +0.8 pp
2024 9.4% CN¥791.21 Million CN¥8.43 Billion CN¥3.78 Billion CN¥2.99 Billion ▼ -3.5 pp
2023 12.9% CN¥1.06 Billion CN¥8.25 Billion CN¥3.25 Billion CN¥2.19 Billion ▼ -3.4 pp
2022 16.3% CN¥1.49 Billion CN¥9.15 Billion CN¥3.69 Billion CN¥2.20 Billion ▲ +1.7 pp
2021 14.6% CN¥1.28 Billion CN¥8.78 Billion CN¥3.59 Billion CN¥2.30 Billion ▼ -1.0 pp
2020 15.7% CN¥1.37 Billion CN¥8.72 Billion CN¥3.50 Billion CN¥2.14 Billion ▲ +7.5 pp
2019 8.1% CN¥637.00 Million CN¥7.82 Billion CN¥3.52 Billion CN¥2.88 Billion ▼ -10.7 pp
2018 18.9% CN¥1.30 Billion CN¥6.89 Billion CN¥3.70 Billion CN¥2.40 Billion ▼ -11.6 pp
2017 30.5% CN¥2.07 Billion CN¥6.78 Billion CN¥3.65 Billion CN¥1.59 Billion ▲ +34.5 pp
2016 -4.0% CN¥-157.92 Million CN¥3.90 Billion CN¥2.41 Billion CN¥2.57 Billion ▼ -7.2 pp
2015 3.1% CN¥90.50 Million CN¥2.88 Billion CN¥1.52 Billion CN¥1.43 Billion ▼ -15.2 pp
2014 18.4% CN¥467.53 Million CN¥2.54 Billion CN¥1.22 Billion CN¥756.80 Million ▼ -57.4 pp
2013 75.8% CN¥291.73 Million CN¥384.95 Million CN¥576.58 Million CN¥284.86 Million ▲ +90.1 pp
2012 -14.4% CN¥-69.06 Million CN¥480.81 Million CN¥509.13 Million CN¥578.19 Million ▲ +31.4 pp
2011 -45.8% CN¥-214.84 Million CN¥469.52 Million CN¥474.07 Million CN¥688.91 Million ▼ -45.7 pp
2010 -0.1% CN¥-507.28K CN¥703.64 Million CN¥408.56 Million CN¥409.07 Million ▼ -29.0 pp
2009 29.0% CN¥264.58 Million CN¥913.15 Million CN¥484.57 Million CN¥219.99 Million ▲ +27.7 pp
2008 1.3% CN¥7.25 Million CN¥570.87 Million CN¥285.21 Million CN¥277.96 Million ▼ -9.8 pp
2007 11.0% CN¥60.58 Million CN¥548.55 Million CN¥396.27 Million CN¥335.69 Million ▲ +22.9 pp
2006 -11.9% CN¥-38.52 Million CN¥324.46 Million CN¥229.40 Million CN¥267.92 Million ▼ -8.9 pp
2005 -2.9% CN¥-9.41 Million CN¥320.93 Million CN¥186.60 Million CN¥196.02 Million ▼ -49.9 pp
2004 47.0% CN¥145.68 Million CN¥309.98 Million CN¥192.16 Million CN¥46.48 Million ▲ +40.6 pp
2003 6.4% CN¥6.05 Million CN¥94.31 Million CN¥79.93 Million CN¥73.88 Million ▼ -11.9 pp
2002 18.3% CN¥14.53 Million CN¥79.43 Million CN¥67.06 Million CN¥52.53 Million ▼ -1.2 pp
2001 19.5% CN¥10.21 Million CN¥52.31 Million CN¥45.26 Million CN¥35.05 Million
pp = percentage points